$8.19
3.76% today
Nasdaq, Nov 20, 10:11 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$8.51
-2.91 25.48% 1M
-9.59 52.98% 6M
-3.53 29.32% YTD
-1.40 14.13% 1Y
+5.57 189.46% 3Y
-4.34 33.77% 5Y
-774,199,991.49 100.00% 10Y
-117,599,999,991.49 100.00% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
-0.14 1.62%

Key metrics

Basic
Market capitalization
$300.5m
Enterprise Value
$211.6m
Net debt
positive
Cash
$88.9m
Shares outstanding
35.3m
Valuation (TTM | estimate)
P/E
425.5 | 224.6
P/S
3.8 | 3.4
EV/Sales
2.7 | 2.4
EV/FCF
17.6
P/B
2.6
Financial Health
Equity Ratio
89.8%
Return on Equity
-38.4%
ROCE
5.1%
ROIC
14.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$79.6m | $87.5m
EBITDA
$6.1m | $24.3m
EBIT
$5.9m | $293.8k
Net Income
$1.2m | $1.3m
Free Cash Flow
$12.0m
Growth (TTM | estimate)
Revenue
251.6% | 135.1%
EBITDA
122.8% | 297.7%
EBIT
122.0% | 102.4%
Net Income
103.5% | 105.1%
Free Cash Flow
146.0%
Margin (TTM | estimate)
Gross
86.3%
EBITDA
7.6% | 27.8%
EBIT
7.4%
Net
1.5% | 1.5%
Free Cash Flow
15.1%
More
EPS
$0.0
FCF per Share
$0.3
Short interest
12.2%
Employees
96
Rev per Employee
$390.0k
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Delcath Systems Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Delcath Systems Inc forecast:

Buy
92%
Hold
8%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
80 80
252% 252%
100%
- Direct Costs 11 11
158% 158%
14%
69 69
273% 273%
86%
- Selling and Administrative Expenses 40 40
36% 36%
50%
- Research and Development Expense 23 23
45% 45%
29%
6.08 6.08
123% 123%
8%
- Depreciation and Amortization 0.20 0.20
54% 54%
0%
EBIT (Operating Income) EBIT 5.88 5.88
122% 122%
7%
Net Profit 1.20 1.20
104% 104%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Business Wire
about one hour ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subj...
Neutral
Business Wire
2 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metastases from Uv...
Neutral
Business Wire
6 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to six individuals whose employment commenced in eit...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 96
Founded 1988
Website delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today